Contact details
Adcock Ingram Critical Care (Pty) Ltd
No.1 Sabax Road, Aeroton
Call: +27 11 494 8000
Fax: +27 11 494 1911
General Queries:
Technical Services:

The Products: Haemophillia Portfolio

Haemophilia is a group of hereditary genetic disorders- recessive sex-linked, X chromosome disorders- that impair the body's ability to control blood clotting or coagulation, which is used to stop bleeding when a blood vessel is broken. Haemophilia A (clotting factor VIII deficiency) is the most common form of the disorder, present in about 1 in 5,000 – 10,000 male births. Haemophilia B (factor IX deficiency) occurs in around 1 in about 20,000 – 34,000 male births.

People with haemophilia use treatment products called factor clotting concentrates. This treatment improves blood clotting and is used to stop or prevent a bleeding episode. Inhibitors develop when the body’s immune system stops accepting the factor (factor VIII for hemophilia A and factor IX for hemophilia B) as a normal part of blood. The body thinks the factor is a foreign substance and tries to destroy it using inhibitors. The inhibitors stop the factor from working. This makes it more difficult to stop a bleeding episode. People with haemophilia who develop an inhibitor do not respond as well to treatment. Inhibitors most often appear during the first year of treatment but they can appear at any time.

Bypassing Agents: Special blood products are used to treat bleeding in people with high levels of inhibitors. They are called bypassing agents. Instead of replacing the missing factor, they go around (or bypass) the factors that are blocked by the inhibitor to help the body form a normal clot. People taking bypassing agents should be monitored closely to make sure the blood is not clotting too much or clotting in the wrong place in the body.

Adcock Ingram Critical Care, markets, sells and distributes a bypassing agent, manufactured by Baxter, to treat these patients with Haemophilia A and Haemophilia B with inhibitors.